Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update

Pharmaceutical Investing

Collegium Pharmaceutical (Nasdaq:COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “In 2017, our focus on operational execution generated significant momentum with Xtampza ER,” said Joe Ciaffoni, Chief Operating Officer of Collegium. “In 2018, the Collegium team …

Collegium Pharmaceutical (Nasdaq:COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“In 2017, our focus on operational execution generated significant momentum with Xtampza ER,” said Joe Ciaffoni, Chief Operating Officer of Collegium. “In 2018, the Collegium team is committed to continuing this focus so that patients who require opioid pain management can benefit from abuse-deterrent Xtampza ER, as well as the Nucynta franchise.”

Click here to read the full press release.

The Conversation (0)
×